Table 2.
Baseline Characteristics of Patients With Germline RET 634 Mutations Excluding Patients With Prophylactic Thyroidectomy for MTC
| Patient Demographics | Subgroup 1 | Group 2 | P Value |
|---|---|---|---|
| (n = 59) | (n = 48) | ||
| Sex | .81 | ||
| Male | 22 (37%) | 19 (40%) | |
| Female | 37 (63%) | 29 (60%) | |
| Race | <.0001 | ||
| Caucasian | 51 (86%) | 23 (48%) | |
| Other | 8 (14%) | 25 (52%) | |
| Age at PHEO diagnosis, ya | 34 (17–60) | n/a | n/a |
| Age at MTC diagnosis, ya | 24 (10–61) | 20 (6–66) | .05 |
| MTC tumor size, cma | 1.5 (0.5–6) | 0.95 (0.15–8) | .06 |
| PHEO tumor size, cma | 3.5 (1–14) | n/a | n/a |
| Family history of MTC | 48 (81%) | 39 (81%) | .87 |
| Family history of PHEO | 39 (66%) | 19 (40%) | .006 |
| PHEO diagnosis secondary to screening | 43 (73%) | n/a | n/a |
| MTC diagnosis secondary to screening | 45 (76%) | 32 (66%) | .46 |
| Median follow-up time for MTC, mo | 249 | 67 | <.01 |
| Median age at last follow-up, y | 46 (22–75) | 28 (6–72) | <.01 |
a
Data represent median (minimum-maximum).